Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-341 in Healthy Volunteers
NCT06281132Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-341 in hypertension (HTN) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve at 72 hours and Maximum Concentration at 72 hours. Started Mar 2024; status: completed.
02
Drugs
CKD-341
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06281132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281132.